ArticleEndoscopy2026
Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett's esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study.
Article in Endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow grade dysplasia (LGD) diagnosed on multiple occasions is considered the strongest risk factor for neoplastic progression in patients with Barrett's esophagus (BE); however, recent studies have shown that aberrant p53 expression may be a more powerful risk factor for progression. This study aimed to compare the association between aberrant p53 expression versus LGD diagnosed on two or more occasions and neoplastic progression risk.
methodsPatients with a BE segment length ≥ 2 cm were included in a multicenter prospective cohort. p53 expression was determined by immunohistochemistry staining. Neoplastic progression was defined as development of high grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Multivariable Cox regression analyses were used to determine the association between selected variables and neoplastic progression risk.
results960 patients (median age 62; 73 % men) were included. During a median (interquartile range) follow-up of 6.3 (3.5-11.9) years, 81 patients (8 %) developed HGD/EAC. p53 expression was aberrant in 24 % of patients, and was strongly associated with an increased risk of progression (hazard ratio [HR] 20.0, 95 %CI 10.0-40.0). In contrast, LGD on multiple occasions was not similarly associated (HR 0.84, 95 %CI 0.47-1.53), after adjustment for age, sex, and segment length. Progression-free survival was better in patients with normal versus aberrant p53 expression, regardless of the histopathological diagnosis (
conclusionsAberrant p53 expression is strongly associated with an increased neoplastic progression risk in BE patients, regardless of the histopathological findings. It may therefore be a better parameter than confirmed LGD on multiple occasions to identify patients who might benefit from ablation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.